Skip to main content
Clinical Trials/NCT06090643
NCT06090643
Active, Not Recruiting
N/A

Implementation Research to Reduce Colorectal Cancer Disparities

Jonsson Comprehensive Cancer Center1 site in 1 country9,745 target enrollmentNovember 1, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Colorectal Carcinoma
Sponsor
Jonsson Comprehensive Cancer Center
Enrollment
9745
Locations
1
Primary Endpoint
Colorectal cancer (CRC) screening rate
Status
Active, Not Recruiting
Last Updated
5 months ago

Overview

Brief Summary

This clinical trial implements research strategies to increase colorectal cancer (CRC) screening rates among low income and ethnic minority groups. CRC is the second most common cause of cancer mortality in the United States and disproportionately burdens low income and ethnic minority groups. Fecal immunochemical testing (FIT) is a test to check for blood in the stool. A brush is used to collect water drops from around the surface of a stool while it is still in the toilet bowl. The samples are then sent to a laboratory, where they are checked for a human blood protein. Blood in the stool may be a sign of colorectal cancer. Despite its potential for reducing CRC incidence and mortality, screening remains woefully underutilized. There is an unmet need for practical and effective programs to improve CRC screening rates. By implementing a culturally-tailored screening CRC program that supports providers and clinic staff to encourage eligible patients to complete FIT, researchers hope to reduce cancer disparities among low-income and ethnic groups and increase the CRC screening rate, which will help providers find CRC sooner, when it may be easier to treat.

Detailed Description

PRIMARY OBJECTIVE: I. To increase CRC screening rates within Northeast Valley Health Corporation (NEVHC). OUTLINE: Clinic sites are randomized to 1 of 2 groups. GROUP I CLINICS: Physicians and clinic staff receive ongoing training, education, and feedback on CRC screening, and utilize point-of-care clinical decision support tool throughout the trial. Patients receive CRC screening recommendations from provider, a FIT kit with culturally tailored instructions, consultation with clinic staff, and text message reminders throughout the trial. GROUP II CLINICS: Physicians and clinic staff provide and patients receive CRC screening usual care throughout the trial.

Registry
clinicaltrials.gov
Start Date
November 1, 2019
End Date
November 1, 2027
Last Updated
5 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • PATIENTS: 50-75 years of age
  • PATIENTS: \>= 1 clinic visit/past 2 years

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Colorectal cancer (CRC) screening rate

Time Frame: Up to 3 years

Patient-level study data on the primary outcome of CRC screening receipt will be assessed through electronic health record data systems. Fecal immunochemical test (FIT) is the screening method most commonly utilized in NEVHC. Patients who have completed a FIT within the past 12 months will be considered screened. Consistent with current CRC screening guidelines, patients screened via a flexible sigmoidoscopy in the past five years (very rare) or colonoscopy (very small numbers) in the past ten years will also be considered screened. The data will be analyzed using generalized linear mixed models that account for clustering within clinic and provider and multiple observations within patients.

Return rate of completed FIT kits

Time Frame: Up to 3 years

The data will be analyzed using generalized linear mixed models that account for clustering within clinic and provider and multiple observations within patients.

Rate of failure to provide a FIT kit to an eligible patient making a clinic visit

Time Frame: Up to 3 years

Missed opportunity rates will be calculated at baseline, end of study, and intermediate time points by determining the number of eligible patients who made a clinic visit but did not receive a FIT kit. The data will be analyzed using generalized linear mixed models that account for clustering within clinic and provider and multiple observations within patients.

Study Sites (1)

Loading locations...

Similar Trials